FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:1009-1019 March 8, 2007 Number 10 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Perspective by Maisel, W. H. Perspective by Farb, A. Editorial by Curfman, G. D. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Maisel, W. H. Related Article by Farb, A. PubMed Citation

ABSTRACT

Background Recent reports have indicated that there may be an increased risk of late stent thrombosis with the use of drug-eluting stents, as compared with bare-metal stents.

Methods We evaluated 6033 patients treated with drug-eluting stents and 13,738 patients treated with bare-metal stents in 2003 and 2004, using data from the Swedish Coronary Angiography and Angioplasty Registry. The outcome analysis covering a period of up to 3 years was based on 1424 deaths and 2463 myocardial infarctions and was adjusted for differences in baseline characteristics.

Results The two study groups did not differ significantly in the composite of death and myocardial infarction during 3 years of follow-up. At 6 months, there was a trend toward a lower unadjusted event rate in patients with drug-eluting stents than in those with bare-metal stents, with 13.4 fewer such events per 1000 patients. However, after 6 months, patients with drug-eluting stents had a significantly higher event rate, with 12.7 more events per 1000 patients per year (adjusted relative risk, 1.20; 95% confidence interval [CI], 1.05 to 1.37). At 3 years, mortality was significantly higher in patients with drug-eluting stents (adjusted relative risk, 1.18; 95% CI, 1.04 to 1.35), and from 6 months to 3 years, the adjusted relative risk for death in this group was 1.32 (95% CI, 1.11 to 1.57).

Conclusions Drug-eluting stents were associated with an increased rate of death, as compared with bare-metal stents. This trend appeared after 6 months, when the risk of death was 0.5 percentage point higher and a composite of death or myocardial infarction was 0.5 to 1.0 percentage point higher per year. The long-term safety of drug-eluting stents needs to be ascertained in large, randomized trials.

Source Information

From the Uppsala Clinical Research Center, Uppsala University Hospital, Uppsala (B.L., S.K.J., J.L., T.N., L.W.); and Linköping University Hospital, Linköping (U.S.) — both in Sweden.

This article (10.1056/NEJMoa067722) was published at www.nejm.org on February 12, 2007.

Address reprint requests to Dr. Lagerqvist at the Uppsala Clinical Research Center, Uppsala University Hospital, 751 85 Uppsala, Sweden, or at bo.lagerqvist{at}ucr.uu.se.

Full Text of this Article

This article has been cited by other articles:

• Wenaweser, P., Daemen, J., Zwahlen, M., van Domburg, R., Juni, P., Vaina, S., Hellige, G., Tsuchida, K., Morger, C., Boersma, E., Kukreja, N., Meier, B., Serruys, P. W., Windecker, S. (2008). Incidence and Correlates of Drug-Eluting Stent Thrombosis in Routine Clinical Practice: 4-Year Results From a Large 2-Institutional Cohort Study. J Am Coll Cardiol 52: 1134-1140 [Abstract] [Full Text]  
• Shishehbor, M. H., Goel, S. S., Kapadia, S. R., Bhatt, D. L., Kelly, P., Raymond, R. E., Galla, J. M., Brener, S. J., Whitlow, P. L., Ellis, S. G. (2008). Long-Term Impact of Drug-Eluting Stents Versus Bare-Metal Stents on All-Cause Mortality. J Am Coll Cardiol 52: 1041-1048 [Abstract] [Full Text]  
• Nallamothu, B. K., Hayward, R. A., Bates, E. R. (2008). Beyond the Randomized Clinical Trial: The Role of Effectiveness Studies in Evaluating Cardiovascular Therapies. Circulation 118: 1294-1303 [Full Text]  
• Nakazawa, G., Finn, A. V., Joner, M., Ladich, E., Kutys, R., Mont, E. K., Gold, H. K., Burke, A. P., Kolodgie, F. D., Virmani, R. (2008). Delayed Arterial Healing and Increased Late Stent Thrombosis at Culprit Sites After Drug-Eluting Stent Placement for Acute Myocardial Infarction Patients: An Autopsy Study. Circulation 118: 1138-1145 [Abstract] [Full Text]  
• Kiaii, B., McClure, R. S., Stewart, P., Rayman, R., Swinamer, S. A., Suematsu, Y., Fox, S., Higgins, J., Albion, C., Kostuk, W. J., Almond, D., Sridhar, K., Teefy, P., Jablonsky, G., Diamantouros, P., Dobkowski, W. B., Jones, P., Bainbridge, D., Iglesias, I., Murkin, J., Cheng, D., Novick, R. J. (2008). Simultaneous integrated coronary artery revascularization with long-term angiographic follow-up. J. Thorac. Cardiovasc. Surg. 136: 702-708 [Abstract] [Full Text]  
• Chieffo, A., Park, S.-J., Meliga, E., Sheiban, I., Lee, M. S., Latib, A., Kim, Y.-H., Valgimigli, M., Sillano, D., Magni, V., Biondi-Zoccai, G., Montorfano, M., Airoldi, F., Rogacka, R., Carlino, M., Michev, I., Lee, C.-W., Hong, M.-K., Park, S.-W., Moretti, C., Bonizzoni, E., Sangiorgi, G. M., Tobis, J., Serruys, P. W., Colombo, A. (2008). Late and very late stent thrombosis following drug-eluting stent implantation in unprotected left main coronary artery: a multicentre registry. Eur Heart J 29: 2108-2115 [Abstract] [Full Text]  
• Anstrom, K. J., Kong, D. F., Shaw, L. K., Califf, R. M., Kramer, J. M., Peterson, E. D., Rao, S. V., Matchar, D. B., Mark, D. B., Harrington, R. A., Eisenstein, E. L. (2008). Long-term Clinical Outcomes Following Coronary Stenting. Arch Intern Med 168: 1647-1655 [Abstract] [Full Text]  
• Austin, D., Oldroyd, K. G., McConnachie, A., Slack, R., Eteiba, H., Flapan, A. D., Jennings, K. P., Northcote, R. J., Pell, A. C.H., Starkey, I. R., Pell, J. P. (2008). Drug-Eluting Stents Versus Bare-Metal Stents for Off-Label Indications: A Propensity Score-Matched Outcome Study. Circ Cardiovasc Intervent 1: 45-52 [Abstract] [Full Text]  
• Brodie, B. R., Stuckey, T., Downey, W., Humphrey, A., Bradshaw, B., Metzger, C., Hermiller, J., Krainin, F., Juk, S., Cheek, B., Duffy, P., Smith, H., Edmunds, J., Varanasi, J., Simonton, C. A., STENT (Strategic Transcatheter Evaluation of New T, (2008). Outcomes and Complications With Off-Label Use of Drug-Eluting Stents: Results From the STENT (Strategic Transcatheter Evaluation of New Therapies) Group. J Am Coll Cardiol Intv 1: 405-414 [Abstract] [Full Text]  
• Holmes, D. R. Jr, Teirstein, P. S., Satler, L., Sketch, M. H. Jr, Popma, J. J., Mauri, L., Wang, H., Schleckser, P. A., Cohen, S. A., SISR Investigators, (2008). 3-Year Follow-Up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) Trial. J Am Coll Cardiol Intv 1: 439-448 [Abstract] [Full Text]  
• Head, D. E., Barash, P. (2008). Progress Is Precarious. Anesth. Analg. 107: 362-364 [Full Text]  
• Newsome, L. T., Kutcher, M. A., Royster, R. L. (2008). Coronary Artery Stents: Part I. Evolution of Percutaneous Coronary Intervention. Anesth. Analg. 107: 552-569 [Abstract] [Full Text]  
• Bates, E. R., Nallamothu, B. K. (2008). Commentary: The Role of Percutaneous Coronary Intervention in ST-Segment-Elevation Myocardial Infarction. Circulation 118: 567-573 [Full Text]  
• Booth, J., Clayton, T., Pepper, J., Nugara, F., Flather, M., Sigwart, U., Stables, R. H., on Behalf of the SoS Investigators, (2008). Randomized, Controlled Trial of Coronary Artery Bypass Surgery Versus Percutaneous Coronary Intervention in Patients With Multivessel Coronary Artery Disease: Six-Year Follow-Up From the Stent or Surgery Trial (SoS). Circulation 118: 381-388 [Abstract] [Full Text]  
• Malenka, D. J., Kaplan, A. V., Lucas, F. L., Sharp, S. M., Skinner, J. S. (2008). Outcomes Following Coronary Stenting in the Era of Bare-Metal vs the Era of Drug-Eluting Stents. JAMA 299: 2868-2876 [Abstract] [Full Text]  
• Alfonso, F. (2008). The "vulnerable" stent why so dreadful?. J Am Coll Cardiol 51: 2403-2406 [Full Text]  
• Dixon, S. R., Grines, C. L., O'Neill, W. W. (2008). The year in interventional cardiology.. J Am Coll Cardiol 51: 2355-2369 [Full Text]  
• Brar, S. S., Kim, J., Brar, S. K., Zadegan, R., Ree, M., Liu, I.-L. A., Mansukhani, P., Aharonian, V., Hyett, R., Shen, A. Y.-J. (2008). Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions.. J Am Coll Cardiol 51: 2220-2227 [Abstract] [Full Text]  
• Choi, S.-H., Prasad, A., Tsimikas, S. (2008). The evolution of thienopyridine therapy clopidogrel duration, diabetes, and drug-eluting stents.. J Am Coll Cardiol 51: 2228-2229 [Full Text]  
• Hamilos, M. I., Ostojic, M., Beleslin, B., Sagic, D., Mangovski, L., Stojkovic, S., Nedeljkovic, M., Orlic, D., Milosavljevic, B., Topic, D., Karanovic, N., Wijns, W., on behalf of the NOBORI CORE Investigators, (2008). Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion.. J Am Coll Cardiol 51: 2123-2129 [Abstract] [Full Text]  
• Muhlestein, J. B. (2008). Endothelial dysfunction associated with drug-eluting stents what, where, when, and how?. J Am Coll Cardiol 51: 2139-2140 [Full Text]  
• Austin, D., Oldroyd, K. G., McConnachie, A., Slack, R., Eteiba, H., Flapan, A. D., Jennings, K. P., Northcote, R. J., Pell, A. C. H., Starkey, I. R., Pell, J. P. (2008). Hospital and operator variations in drug-eluting stent use: a multi-level analysis of 5967 consecutive patients in Scotland. J Public Health (Oxf) 30: 186-193 [Abstract] [Full Text]  
• Li, J., Jabara, R., Pendyala, L., Otsuka, Y., Shinke, T., Hou, D., Robinson, K., Chronos, N. (2008). Abnormal Vasomotor Function of Porcine Coronary Arteries Distal to Sirolimus-Eluting Stents. J Am Coll Cardiol Intv 1: 279-285 [Abstract] [Full Text]  
• Becker, R. C., Meade, T. W., Berger, P. B., Ezekowitz, M., O'Connor, C. M., Vorchheimer, D. A., Guyatt, G. H., Mark, D. B., Harrington, R. A. (2008). The Primary and Secondary Prevention of Coronary Artery Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 776S-814S [Abstract] [Full Text]  
• Groeneveld, P. W., Matta, M. A., Greenhut, A. P., Yang, F. (2008). Drug-Eluting Compared With Bare-Metal Coronary Stents Among Elderly Patients. J Am Coll Cardiol 51: 2017-2024 [Abstract] [Full Text]  
• Anderson, H. V. (2008). Drug-Eluting Stents: Life Insurance With a Better Death Benefit. J Am Coll Cardiol 51: 2025-2027 [Full Text]  
• Bhatt, S. H, Hauser, T. H (2008). Very Late Stent Thrombosis After Dual Antiplatelet Therapy Discontinuation in a Patient with a History of Acute Stent Thrombosis. The Annals of Pharmacotherapy 42: 708-712 [Abstract] [Full Text]  
• Wallentin, L. (2008). Dual antiplatelet therapy in the drug-eluting stent era. Eur Heart J Suppl 10: D38-D44 [Abstract] [Full Text]  
• Mauri, L., Normand, S.-L. T. (2008). Studies of Drug-Eluting Stents: To Each His Own?. Circulation 117: 2047-2050 [Full Text]  
• Hannan, E. L., Racz, M., Holmes, D. R., Walford, G., Sharma, S., Katz, S., Jones, R. H., King, S. B. III (2008). Comparison of Coronary Artery Stenting Outcomes in the Eras Before and After the Introduction of Drug-Eluting Stents. Circulation 117: 2071-2078 [Abstract] [Full Text]  
• Kapadia, M. R., Popowich, D. A., Kibbe, M. R. (2008). Modified Prosthetic Vascular Conduits. Circulation 117: 1873-1882 [Abstract] [Full Text]  
• Hannan, E. L., Racz, M., Walford, G., Holmes, D. R., Jones, R. H., Sharma, S., Katz, S., King, S. B. III (2008). Drug-Eluting Versus Bare-Metal Stents in the Treatment of Patients With ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol Intv 1: 129-135 [Abstract] [Full Text]  
• Grines, C. L., Goldstein, J. A., Safian, R. D. (2008). Should We Routinely Use Drug-Eluting Stents for Acute Myocardial Infarction?: Let's Wait and See. J Am Coll Cardiol Intv 1: 136-138 [Full Text]  
• Marso, S. P. (2008). Diabetes and Drug-Eluting Stents: What You Get and What You Don't. J Am Coll Cardiol Intv 1: 148-149 [Full Text]  
• Di Mario, C., Barlis, P. (2008). Optical Coherence Tomography: A New Tool to Detect Tissue Coverage in Drug-Eluting Stents. J Am Coll Cardiol Intv 1: 174-175 [Full Text]  
• Pinto Slottow, T. L., Waksman, R. (2008). Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel Meeting on the Endeavor Zotarolimus-Eluting Coronary Stent. Circulation 117: 1603-1608 [Full Text]  
• Pfisterer, M., Brunner-La Rocca, H. P., Kaiser, C. (2008). The balance of risks and benefits of drug-eluting versus bare-metal stents.. J Am Coll Cardiol 51: 972-972 [Full Text]  
• Thuesen, L., Jensen, L. O., Kaltoft, A., Maeng, M. (2008). Reply.. J Am Coll Cardiol 51: 972-973 [Full Text]  
• Ryding, A D S, Banning, A P (2008). Which patients receiving warfarin can be treated safely with a drug-eluting stent?. Heart 94: 275-277 [Full Text]  
• Ortolani, P., Balducelli, M., Marzaroli, P., Piovaccari, G., Menozzi, A., Guiducci, V., Sangiorgio, P., Tarantino, F., Geraci, G., Castriota, F., Tondi, S., Saia, F., Cooke, R. M.T., Guastaroba, P., Grilli, R., Marzocchi, A., Maresta, A. (2008). Two-Year Clinical Outcomes With Drug-Eluting Stents for Diabetic Patients With De Novo Coronary Lesions: Results From a Real-World Multicenter Registry. Circulation 117: 923-930 [Abstract] [Full Text]  
• Applegate, R. J., Sacrinty, M. T., Kutcher, M. A., Santos, R. M., Gandhi, S. K., Baki, T. T., Little, W. C. (2008). "Off-label" stent therapy 2-year comparison of drug-eluting versus bare-metal stents.. J Am Coll Cardiol 51: 607-614 [Abstract] [Full Text]  
• Grines, C. L. (2008). Off-label use of drug-eluting stents putting it in perspective.. J Am Coll Cardiol 51: 615-617 [Full Text]  
• Jeremias, A., Kirtane, A. (2008). Balancing Efficacy and Safety of Drug-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention. ANN INTERN MED 148: 234-238 [Abstract] [Full Text]  
• Saia, F., Marzocchi, A., Branzi, A. (2008). Review: The safety of drug-eluting stents. Therapeutic Advances in Cardiovascular Disease 2: 43-52 [Abstract]  
• Austin, D., Pell, J. P, Oldroyd, K. G (2008). Drug-eluting stents: do the risks really outweigh the benefits?. Heart 94: 127-128 [Full Text]  
• Melikian, N, Wijns, W (2008). Drug-eluting stents: a critique. Heart 94: 145-152 [Abstract] [Full Text]  
• Holmes, D. R. Jr, Gersh, B. J., Whitlow, P., King, S. B. III, Dove, J. T. (2008). Percutaneous Coronary Intervention for Chronic Stable Angina: A Reassessment. J Am Coll Cardiol Intv 1: 34-43 [Abstract] [Full Text]  
• Marroquin, O. C., Selzer, F., Mulukutla, S. R., Williams, D. O., Vlachos, H. A., Wilensky, R. L., Tanguay, J.-F., Holper, E. M., Abbott, J. D., Lee, J. S., Smith, C., Anderson, W. D., Kelsey, S. F., Kip, K. E. (2008). A Comparison of Bare-Metal and Drug-Eluting Stents for Off-Label Indications. NEJM 358: 342-352 [Abstract] [Full Text]  
• Carrozza, J. P. Jr. (2008). Drug-Eluting Stents -- Pushing the Envelope beyond the Labels?. NEJM 358: 405-407 [Full Text]  
• Wijns, W., Braunwald, E. (2007). Advancing the Knowledge Base on the Efficacy Safety Ratio With Drug-Eluting Stents: Contributions From the European Society of Cardiology Congress, Vienna, Austria, September 1 5, 2007. J Am Coll Cardiol 50: 2431-2433 [Full Text]  
• Unger, F. (2007). Drug eluting stents a nightmare?. ICVTS 6: 813-814 [Abstract] [Full Text]  
• Abbott, J. D., Voss, M. R., Nakamura, M., Cohen, H. A., Selzer, F., Kip, K. E., Vlachos, H. A., Wilensky, R. L., Williams, D. O. (2007). Unrestricted Use of Drug-Eluting Stents Compared With Bare-Metal Stents in Routine Clinical Practice: Findings From the National Heart, Lung, and Blood Institute Dynamic Registry. J Am Coll Cardiol 50: 2029-2036 [Abstract] [Full Text]  
• Buttner, H. J., Neumann, F.-J. (2007). Peeling-Off Labels: Mounting Evidence for Benefit of Drug-Eluting Stents With Off-Label Use. J Am Coll Cardiol 50: 2037-2038 [Full Text]  
• Lamas, G. A, Hochman, J. S (2007). Where does the Occluded Artery Trial leave the late open artery hypothesis?. Heart 93: 1319-1321 [Abstract] [Full Text]  
• Fleisher, L. A., Beckman, J. A., Brown, K. A., Calkins, H., Chaikof, E. L., Fleischmann, K. E., Freeman, W. K., Froehlich, J. B., Kasper, E. K., Kersten, J. R., Riegel, B., Robb, J. F., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Buller, C. E., Creager, M. A., Ettinger, S. M., Faxon, D. P., Fuster, V., Halperin, J. L., Hiratzka, L. F., Hunt, S. A., Lytle, B. W., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B., Tarkington, L. G., Yancy, C. W. (2007). ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. J Am Coll Cardiol 50: e159-e242 [Full Text]  
• Windecker, S., Meier, B. (2007). Late Coronary Stent Thrombosis. Circulation 116: 1952-1965 [Full Text]  
• Fleisher, L. A., Beckman, J. A., Brown, K. A., Calkins, H., Chaikof, E. L., Fleischmann, K. E., Freeman, W. K., Froehlich, J. B., Kasper, E. K., Kersten, J. R., Riegel, B., Robb, J. F. (2007). ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Circulation 116: e418-e500 [Full Text]  
• Riddell, J. W., Chiche, L., Plaud, B., Hamon, M. (2007). Coronary Stents and Noncardiac Surgery. Circulation 116: e378-e382 [Full Text]  
• Tu, J. V., Bowen, J., Chiu, M., Ko, D. T., Austin, P. C., He, Y., Hopkins, R., Tarride, J.-E., Blackhouse, G., Lazzam, C., Cohen, E. A., Goeree, R. (2007). Effectiveness and Safety of Drug-Eluting Stents in Ontario. NEJM 357: 1393-1402 [Abstract] [Full Text]  
• Farag, N., Delbanco, T., Carrozza, J. P. Jr (2007). Update: A 69-Year-Old Woman With Left Main Coronary Artery Disease. JAMA 298: 1558-1559 [Full Text]  
• Chassot, P.-G., Delabays, A., Spahn, D. R. (2007). Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction. Br J Anaesth 99: 316-328 [Abstract] [Full Text]  
• Daemen, J., Serruys, P. W. (2007). Drug-Eluting Stent Update 2007: Part II: Unsettled Issues. Circulation 116: 961-968 [Full Text]  
• Bavry, A. A., Bhatt, D. L. (2007). Drug-Eluting Stents: Dual Antiplatelet Therapy for Every Survivor?. Circulation 116: 696-699 [Full Text]  
• Bode, C., Zehender, M. (2007). The use of antiplatelet agents following percutaneous coronary intervention: focus on late stent thrombosis. Eur Heart J Suppl 9: D10-D19 [Abstract] [Full Text]  
• Jensen, L. O., Maeng, M., Kaltoft, A., Thayssen, P., Hansen, H. H. T., Bottcher, M., Lassen, J. F., Krussel, L. R., Rasmussen, K., Hansen, K. N., Pedersen, L., Johnsen, S. P., Soerensen, H. T., Thuesen, L. (2007). Stent Thrombosis, Myocardial Infarction, and Death After Drug-Eluting and Bare-Metal Stent Coronary Interventions. J Am Coll Cardiol 50: 463-470 [Abstract] [Full Text]  
• Vermeersch, P., Agostoni, P., Verheye, S., Van den Heuvel, P., Convens, C., Van den Branden, F., Van Langenhove, G., DELAYED RRISC (Death and Events at Long-term follo, (2007). Increased Late Mortality After Sirolimus-Eluting Stents Versus Bare-Metal Stents in Diseased Saphenous Vein Grafts: Results From the Randomized DELAYED RRISC Trial. J Am Coll Cardiol 50: 261-267 [Abstract] [Full Text]  
• Ellis, S. G. (2007). "Crying Fire in a Theater" or a "Confirmatory Sighting?". J Am Coll Cardiol 50: 268-269 [Full Text]  
• Kastrati, A., Schomig, A. (2007). Drug-Eluting Stents: Is Their Future as Bright as Their Past?. J Am Coll Cardiol 50: 146-148 [Full Text]  
• Kaul, S., Shah, P. K., Diamond, G. A. (2007). As Time Goes By: Current Status and Future Directions in the Controversy Over Stenting. J Am Coll Cardiol 50: 128-137 [Abstract] [Full Text]  
• Jaffe, R., Strauss, B. H. (2007). Late and Very Late Thrombosis of Drug-Eluting Stents: Evolving Concepts and Perspectives. J Am Coll Cardiol 50: 119-127 [Abstract] [Full Text]  
• Holmes, D. R. Jr, Kereiakes, D. J., Laskey, W. K., Colombo, A., Ellis, S. G., Henry, T. D., Popma, J. J., Serruys, P. W.J.C., Kimura, T., Williams, D. O., Windecker, S., Krucoff, M. W. (2007). Thrombosis and Drug-Eluting Stents: An Objective Appraisal. J Am Coll Cardiol 50: 109-118 [Abstract] [Full Text]  
• Spinler, S. A., Wilensky, R. L. (2007). Duration of clopidogrel therapy after placement of drug-eluting intracoronary stent. Am J Health Syst Pharm 64: 1432-1434 [Full Text]  
• (2007). JournalScan. Heart 93: 890-892 [Full Text]  
• Finn, A. V., Nakazawa, G., Joner, M., Kolodgie, F. D., Mont, E. K., Gold, H. K., Virmani, R. (2007). Vascular Responses to Drug Eluting Stents: Importance of Delayed Healing. Arterioscler. Thromb. Vasc. Bio. 27: 1500-1510 [Abstract] [Full Text]  
• Krucoff, M. W., Boam, A., Schultz, D. G. (2007). Drug-Eluting Stents "Deliver Heartburn": How Do We Spell Relief Going Forward?. Circulation 115: 2990-2994 [Full Text]  
• Dove, J. T., Moliterno, D. J., Weaver, W. D., Shelton, M. E. (2007). President's Page: Drug-Eluting Stents in Contemporary Practice--A Call for a Real-World, Open-Entry, Device-Tracking Registry. J Am Coll Cardiol 49: 2223-2226 [Full Text]  
• Beohar, N., Davidson, C. J., Kip, K. E., Goodreau, L., Vlachos, H. A., Meyers, S. N., Benzuly, K. H., Flaherty, J. D., Ricciardi, M. J., Bennett, C. L., Williams, D. O. (2007). Outcomes and Complications Associated With Off-Label and Untested Use of Drug-Eluting Stents. JAMA 297: 1992-2000 [Abstract] [Full Text]  
• Win, H. K., Caldera, A. E., Maresh, K., Lopez, J., Rihal, C. S., Parikh, M. A., Granada, J. F., Marulkar, S., Nassif, D., Cohen, D. J., Kleiman, N. S., for the EVENT Registry Investigators, (2007). Clinical Outcomes and Stent Thrombosis Following Off-Label Use of Drug-Eluting Stents. JAMA 297: 2001-2009 [Abstract] [Full Text]  
• Harrington, R. A., Ohman, E. M. (2007). The Enigma of Drug-Eluting Stents: Hope, Hype, Humility, and Advancing Patient Care. JAMA 297: 2028-2030 [Full Text]  
• Boden, W. E., O'Rourke, R. A., Teo, K. K., Hartigan, P. M., Maron, D. J., Kostuk, W. J., Knudtson, M., Dada, M., Casperson, P., Harris, C. L., Chaitman, B. R., Shaw, L., Gosselin, G., Nawaz, S., Title, L. M., Gau, G., Blaustein, A. S., Booth, D. C., Bates, E. R., Spertus, J. A., Berman, D. S., Mancini, G.B. J., Weintraub, W. S., the COURAGE Trial Research Group, (2007). Optimal Medical Therapy with or without PCI for Stable Coronary Disease. NEJM 356: 1503-1516 [Abstract] [Full Text]  
• Curfman, G. D., Morrissey, S., Jarcho, J. A., Drazen, J. M. (2007). Drug-Eluting Coronary Stents -- Promise and Uncertainty. NEJM 356: 1059-1060 [Full Text]